- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07291427
Chronic Subdural Hematoma Embolization With Detachable Coils (SEED)
Safety and Efficacy of Chronic Subdural Hematoma Embolization With Detachable Coils
This is a prospective, multi-center, post market registry study designed to evaluate the safety and efficacy of treatment with Balt coils in patients with chronic subdural hematoma (cSDH).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The primary objective of this observational registry study is to assess the safety and efficacy of Balt Coils as an adjunct to middle meningeal artery (MMA) embolization in a real-world setting among patients undergoing treatment for chronic subdural hematoma (cSDH), and explore correlations between patient characteristics, clinical characteristics, and outcomes. By collecting comprehensive, real-world data, the registry will characterize procedural inputs, document clinical and radiographic outcomes, and explore variation in technique and practice setting. The overarching goal is to generate a more complete understanding of Middle Meningeal Artery Embolization (MMAE) in diverse clinical environments, inform future prospective studies, and guide evidence-based adoption of this evolving therapy. Patients may be treated with Balt coils regardless of enrollment in the study as the decision to place the coils should be made independently as per standard of care and prior to enrollment in the study.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Sukaina Davdani
- Phone Number: (212) 241-2524
- Email: Sukaina.Davdani@mountsinai.org
Study Contact Backup
- Name: Sydney Edwards
- Phone Number: (212) 241-2524
- Email: Sydney.Edwards@mountsinai.org
Study Locations
-
-
Arizona
-
Tucson, Arizona, United States, 85711
- Not yet recruiting
- Carondelet Neurological Institute
-
Principal Investigator:
- Alexander Coon, MD
-
Contact:
- Matthew Pohlmeyer
- Email: Matthew.Pohlmeyer@tenethealth.org
-
-
California
-
San Deigo, California, United States, 92093
- Not yet recruiting
- University of California - San Deigo
-
Contact:
- Pete Chase
- Email: PChase@Health.UCSD.edu
-
Principal Investigator:
- David Santiago-Dieppa, MD
-
Walnut Creek, California, United States, 94598
- Recruiting
- John Muir Health
-
Principal Investigator:
- Benjamin Yim, MD
-
Contact:
- Melenie Aaron
- Email: Melenie.Aaron@JohnMuirHealth.com
-
-
Kentucky
-
Louisville, Kentucky, United States, 40292
- Not yet recruiting
- University of Louisville
-
Contact:
- Mechelle Kaufman
- Email: Mechelle.Kaufman@louisville.edu
-
Principal Investigator:
- Isaac Josh Abecassis, MD
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- Not yet recruiting
- Oklahoma University Medical Center
-
Principal Investigator:
- Hakeem Shakir, MD
-
Contact:
- Michael Omimi
- Email: Michael-Omini@OU.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Patients with symptomatic chronic subdural hematoma (cSDH), with or without previous surgical evacuation that need additional treatment
Description
Inclusion criteria:
- Age ≥ 18
- Patients experiencing unilateral or bilateral non-acute subdural hematoma confirmed by CT imaging. Acute on Chronic or mixed density hematoma allowed.
- A clinical decision has been made to use coiling and/or embolics as treatment, with or without surgical debridement, independently as per standard of care and prior to enrollment in the study.
- Signed informed consent obtained by patient or Legal Authorized Representative (LAR)
Exclusion criteria:
- Primary acute SDH
- Prior MMAE in target territory
- Premorbid mRS > 3
- Common carotid stenosis >70% or prior carotid stent placement
- Significant medical contraindication to angiography (kidney failure/disease)
- Anatomical variations that would make MMA embolization difficult or unsafe
- Currently participating in an investigational (drug, device, etc.) clinical trial that may confound study endpoints
- Pregnancy
- Life expectancy ≤ 1 year
Study Plan
How is the study designed?
Design Details
- Observational Models: CASE_ONLY
- Time Perspectives: PROSPECTIVE
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Participants with cSDH
All participants enrolled will be treated with the Balt coils.
|
MMA embolization utilizing Balt Coils
Other Names:
surgical or bedside evacuation pre or post-surgical debridement |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in hematoma volume
Time Frame: 180 days
|
Change in hematoma volume based on CT imaging |
180 days
|
|
Change in maximal thickness
Time Frame: 180 days
|
Change in maximal thickness based on CT imaging |
180 days
|
|
Change in midline shift
Time Frame: 180 days
|
Change in midline shift (mm) based on CT imaging |
180 days
|
|
Number of periprocedural major disabling stroke or any death
Time Frame: 30 days
|
Number of periprocedural major disabling stroke or any death |
30 days
|
|
Number of participants with symptomatic recurrence progression requiring retreatment
Time Frame: 180 days
|
Number of participants with symptomatic recurrence progression of the SDH requiring retreatment |
180 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Device-related adverse events (AE), serious adverse events (SAE), and procedural-related SAE
Time Frame: 180 days
|
Number of Adverse events and serious adverse events related to the device as assessed by an independent medical monitor |
180 days
|
|
Number of Acute successful embolization of the target vessel
Time Frame: Immediately post-procedure
|
Determination of successful embolization based on angiographic imaging |
Immediately post-procedure
|
|
Change in EuroQoL 5 dimensions 5 levels (EQ-5D-5L)
Time Frame: 180 days
|
The EQ-5D is a generic instrument for describing and valuing health. The new version includes the 5 levels of severity in each of the existing five EQ-5D dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, and now called the EQ-5D-5L, each assessed on a 5-point scale (1=no problem, 2=slight problems, 3=moderate problems, 4=severe problems, 5=extreme problems). Participants score each dimension based on their health that day and their responses are used to generate a health index score. Index scores could range from <0 (a health state equivalent to dead with negative values representing a state worse than dead) to 1 (full health). Lower scores indicate a higher QoL. |
180 days
|
Collaborators and Investigators
Investigators
- Principal Investigator: Christopher Kellner, Icahn School of Medicine at Mount Sinai
- Principal Investigator: Benjamin Yim, John Muir Health
- Principal Investigator: Alexander Coon, Carondelet Neurological Institute
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Vascular Diseases
- Cardiovascular Diseases
- Wounds and Injuries
- Pathologic Processes
- Chronic Disease
- Disease Attributes
- Hemorrhage
- Craniocerebral Trauma
- Trauma, Nervous System
- Intracranial Hemorrhages
- Intracranial Hemorrhage, Traumatic
- Pathological Conditions, Signs and Symptoms
- Hematoma
- Hematoma, Subdural
- Hematoma, Subdural, Chronic
Other Study ID Numbers
- STUDY-25-01365
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Upon the completion of the study, Mount Sinai's data management team will clean and analyze all data in preparation of manuscript writing and publication. Data that will be shared and published will be that of all participants combined to protect individual patient privacy and confidentiality.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.